Abstract : This thesis presents a complete work relating to methodology developed for the neurophysiologic and clinical exploitation of a Positron Emission Tomography (PET) tracer. The case of [18F]MPPF, antagonist PET tracer specific of serotoninergic 5-HT1A receptor is the object of application. Experimental procedures and developments include: I/ A compartmental modelling procedure of the in vivo ligand-receptor exchanges sustained by a multi-injection [18F]MPPF PET experiment performed on a small group of healthy men, II/ Research and validation of a simplified modelling procedure with tissue reference based on mono-injection protocol, III/ Constitution of a normative database of the 5-HT1A binding by the [18F]MPPF in a healthy population of women and men from 20 to 65 years old, IV/ A reliability test-retest study for the [18F]MPPF binding measurement, V/ The constitution of a Monte-Carlo simulated database of [18F]MPPF acquisitions for the development and validation of data processing methods.
Simulated database has been used to validate a partial volume effect correction processing method, and for a detectability study of the endogenous ligand discharge.
Modelling and normative experimental data have been used in several clinical studies.
This works constitutes an important phasis in a tracer development: it takes place between biological experimentation on animals and the human clinical use of a tracer.